LONDON, June 18, 2010 /PRNewswire/ -- An article recently published in The Lancet reports that using an artificial pancreas system overnight can significantly reduce the risk of nocturnal hypoglycemia in children and adolescents with type 1 diabetes.(1) Moreover, the first clinical trial of an artificial pancreas system delivering both insulin and glucagon has shown that this system can prevent development of hypoglycemia.(2) The latest issue of the journal Diabetic Hypoglycemia (http://www.hypodiab.com) reviews advances in artificial pancreas design and production in further detail.
Dr Roman Hovorka, a leading artificial pancreas researcher and author of the Lancet paper(1) discusses developments in the field of closed-loop insulin delivery and reviews system components and challenges to the introduction of this technology into clinical practice, including the need for superfast-acting insulin analogs, dual hormone approaches to accelerate insulin absorption, and optimization of the clinical infrastructure to support the use of closed-loop systems.
Professor Simon Heller's related editorial details how technological
developments supporting diabetes self-management have so far failed to lead
to major improvements in glycemic control or to consistently reduced rates of
severe hypoglycemia. He explains that one reason may be the requirement for
patients to estimate both basal and prandial insulin doses, which can be
demanding for many patients and may lead to ineffective diabetes
self-management. Professor Heller discusses how the i
|SOURCE ESP Bioscience|
Copyright©2010 PR Newswire.
All rights reserved